FDA-cleared profile

KOALA

IB Lab GmbH · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: The Knee OsteoArthritis Labeling Assistant (KOALA) software provides metric measurements of the joint space width and indicators for presence or absence of radiographic features of osteoarthritis (OA) on PA/AP knee X-ray images.

Clinical role
Image processing software that provides joint space width measurements and presence/absence indicators of radiographic osteoarthritis features on PA/AP knee X-rays, summarized in a report viewed on a DICOM viewer workstation; not for use in lieu of full patient evaluation.
Images and patients
X-ray/Radiography · MSK
Key limitation
Keep in mind: It should not be used in-lieu of full patient evaluation or solely relied upon to make or confirm a diagnosis.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: The Knee OsteoArthritis Labeling Assistant (KOALA) software provides metric measurements of the joint space width and indicators for presence or absence of radiographic features of osteoarthritis (OA) on PA/AP knee X-ray images.
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: MSK Input: DICOM compliant images collected in other devices in either digitally computed (CR) or directly digital (DX) formats; standing, fixed-flexion radiographs of the knee.
  • Who uses it?Intended users: Trained professionals including radiologists, orthopedics, physicians, and medical technicians
  • What does the software produce?Output: KOALA outputs a report including: minimum joint space width measurements (medial and lateral); presence or absence of sclerosis, joint space narrowing, and osteophytes based on OARSI criteria; and presence or absence of radiographic knee OA based on Kellgren & Lawrence grading. Results are summarized in a KOALA report viewable on any FDA-approved DICOM viewer workstation.
  • What is its most important limitation?Key limitation: It should not be used in-lieu of full patient evaluation or solely relied upon to make or confirm a diagnosis.

Clinical takeaway. Clinical role: The Knee OsteoArthritis Labeling Assistant (KOALA) software provides metric measurements of the joint space width and indicators for presence or absence of radiographic features of osteoarthritis (OA) on PA/AP knee X-ray images.

Evidence takeaway. Evidence from the reviewed source record: Software verification and validation testing was completed for the subject device. The software functioned as intended and all results observed were as expected. Standalone clinical performance validation was performed on a dataset containing 6597 radiographs, representing 1149 individuals.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
The Knee OsteoArthritis Labeling Assistant (KOALA) software provides metric measurements of the joint space width and indicators for presence or absence of radiographic features of osteoarthritis (OA) on PA/AP knee X-ray images.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Image processing software that provides joint space width measurements and presence/absence indicators of radiographic osteoarthritis features on PA/AP knee X-rays, summarized in a report viewed on a DICOM viewer workstation; not for use in lieu of full patient evaluation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The Knee OsteoArthritis Labeling Assistant (KOALA) software provides metric measurements of the joint space width and indicators for presence or absence of radiographic features of osteoarthritis (OA) on posterior-anterior or anterior-posterior (PA/AP) knee X-ray images." … "Outputs are summarized in a KOALA report that can be viewed on any FDA approved DICOM viewer workstation.". Read from the exact FDA decision document on 2026-11-14.

Required input
DICOM compliant images collected in other devices in either digitally computed (CR) or directly digital (DX) formats; standing, fixed-flexion radiographs of the knee.
  • Exact FDA submission
  • Checked 2026-09-19

The exact summary specifies DICOM, CR/DX image formats, and standing fixed-flexion knee radiographs rather than generic MSK radiography.

Output and clinician action
KOALA outputs a report including: minimum joint space width measurements (medial and lateral); presence or absence of sclerosis, joint space narrowing, and osteophytes based on OARSI criteria; and presence or absence of radiographic knee OA based on Kellgren & Lawrence grading. Results are summarized in a KOALA report viewable on any FDA-approved DICOM viewer workstation.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Trained professionals including radiologists, orthopedics, physicians, and medical technicians
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Limitations
It should not be used in-lieu of full patient evaluation or solely relied upon to make or confirm a diagnosis.
  • Exact FDA submission
  • Checked 2026-09-19

This is the exact packet limitation; the ACR scanner-manufacturer label is not an FDA limitation statement.

Evidence summary
Software verification and validation testing was completed for the subject device. The software functioned as intended and all results observed were as expected. Standalone clinical performance validation was performed on a dataset containing 6597 radiographs, representing 1149 individuals.
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet supports verification/validation and the 6597-radiograph, 1149-individual dataset; it does not support the dossier's single aggregated sensitivity/specificity values.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Software verification and validation testing was completed for the subject device. The software functioned as intended and all results observed were as expected. Standalone clinical performance validation was performed on a dataset containing 6597 radiographs, representing 1149 individuals.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet supports verification/validation and the 6597-radiograph, 1149-individual dataset; it does not support the dossier's single aggregated sensitivity/specificity values.

Reported sensitivity
84.50%
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
80.50%
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

KOALA regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K192109
  • Samplen=1149
  • IndependenceIndependence not established

K192109

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K192109. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM compliant images collected in other devices in either digitally computed (CR) or directly digital (DX) formats; standing, fixed-flexion radiographs of the knee.

    Scope: Exact FDA submission. The exact summary specifies DICOM, CR/DX image formats, and standing fixed-flexion knee radiographs rather than generic MSK radiography.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K192109: KOALA

  2. Routing

    Source context, not route validation: The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.

    Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-01 · KOALA model card (K192109)

  3. AI processing

    Source context, not route validation: The exact FDA package describes KOALA running on a server and operating in a Linux environment, deployable to be compatible with any operating system supporting the third-party software Docker. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "KOALA operates in a Linux environment and can be deployed to be compatible with any operating system supporting the third-party software Docker." … "Runs on Server Yes Yes Yes". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K192109: KOALA

  4. Returned objects

    Source context, not route validation: KOALA outputs a report including: minimum joint space width measurements (medial and lateral); presence or absence of sclerosis, joint space narrowing, and osteophytes based on OARSI criteria; and presence or absence of radiographic knee OA based on Kellgren & Lawrence grading. Results are summarized in a KOALA report viewable on any FDA-approved DICOM viewer workstation.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K192109: KOALA

  5. Viewer/worklist/report

    Unresolved route: KOALA outputs a report including: minimum joint space width measurements (medial and lateral); presence or absence of sclerosis, joint space narrowing, and osteophytes based on OARSI criteria; and presence or absence of radiographic knee OA based on Kellgren & Lawrence grading. Results are summarized in a KOALA report viewable on any FDA-approved DICOM viewer workstation.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K192109: KOALA

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes KOALA running on a server and operating in a Linux environment, deployable to be compatible with any operating system supporting the third-party software Docker. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "KOALA operates in a Linux environment and can be deployed to be compatible with any operating system supporting the third-party software Docker." … "Runs on Server Yes Yes Yes". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-09-01

Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

Training
The 510(k) summary states IB Lab KOALA is to be used by trained professionals including, but not limited to, radiologists, orthopedics, physicians and medical technicians.
  • Exact FDA submission
  • Checked 2026-10-27

User qualification wording only; the summary specifies no training program or training offering for this device.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Result destination

workstation is explicitly referenced as a result destination.

exact submission · checked 2026-09-01

Confirm supported products, versions, routing behavior, and display requirements during local evaluation.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for KOALA; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K192109
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
MSK
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact summary identifies the anatomical area as joint (knee); it does not use the dossier's broad MSK label. Controlled directory display reconciled from exact FDA wording: Joint (knee). -> MSK.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2019-11-05
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
10Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K192109 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K192109: KOALA

    U.S. Food and Drug Administration - Published 2019-11-05 - Accessed 2026-09-19

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, output, input, limitations, evidenceSummary, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. KOALA model card (K192109)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K192109

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

Research history

  1. K192109 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251408

OsteoSight™ Hip (v1)

Naitive Technologies Ltd

Authorized purpose: Opportunistically analyzes standard AP hip or pelvis radiographs in patients aged 50 years and older and issues a report when the estimated femoral-neck BMD is below a preset threshold to prompt clinical bone-health assessment; absence of a report does not rule out low BMD.

Modality
X-ray/Radiography
Anatomy
MSK
Decision
2025-09-02
FDA-cleared K242171

TechCare Trauma

Milvue

Authorized purpose: Aids clinicians and radiologists reviewing 2D X-ray radiographs by detecting, localizing, and characterizing fractures across the FDA-listed appendicular, hip/pelvis, clavicle, and thorax/rib examinations, and by detecting elbow joint effusion on lateral elbow or forearm views in children/adolescents and adults; results are not standalone clinical decisions.

Modality
X-ray/Radiography
Anatomy
MSK
Decision
2025-01-17
FDA-cleared K240845

Rayvolve

AZmed SAS

Authorized purpose: Assists radiologists and emergency physicians in detecting fractures on DICOM musculoskeletal radiographs for adults and children aged 2 years or older, limited to the FDA-listed anatomic areas and standard views (ankle, clavicle, elbow, forearm, hip, humerus, knee, pelvis, shoulder, tibia/fibula, wrist, hand, and foot); it is an aided-diagnosis device and does not operate autonomously.

Modality
X-ray/Radiography
Anatomy
MSK
Decision
2024-07-17
FDA-cleared K193417

FractureDetect (FX)

Imagen Technologies, Inc.

Authorized purpose: Assists clinicians in detecting fractures during review of adult musculoskeletal radiographs.

Modality
X-ray/Radiography
Anatomy
MSK
Decision
2020-07-30

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history